抗体D5F3及Survivin在非小细胞肺癌患者中的临床应用价值
Clinical value of antibody D5F3 and Survivin in non small cell lung cancer
叶韶峰 1许朝阳 2吴明3
作者信息
- 1. 建德市第一人民医院 胸外科,浙江 建德 311600
- 2. 建德市第一人民医院 病理科,浙江 建德 311600
- 3. 浙江大学医学院附属第二医院胸外科,浙江 杭州 310009
- 折叠
摘要
目的 探究抗体D5F3 及Survivin 在非小细胞肺癌患者中的临床应用价值.方法 选取2012年10月～2014年6月期间于建德市第一人民医院经RT-PCR 检测的200 例非小细胞肺癌患者的石蜡包埋标本(包括EML4-ALK 突变型和野生型),应用ALK新型抗体D5F3 及Survivin(CST 公司生产)检测该基因蛋白表达情况,分别从阴性、阳性(+～3 +)进行对比其敏感性和特异性.结果 检测结果显示,(+)符合率为15.78％,(++)符合率为27.27％,(+++)符合率为87.5％,差异有统计学意义( P<.0.05),Survivin蛋白在NSCLC组织中的表达与临床病理特征的关系Survivin蛋白表达的阳性率与分化程度相关( P<.0.05),而与其他临床病理特征无相关,随分化程度降低,Survivin 蛋白表达的阳性率显著增加.结论 D5F3及Survivin抗体在NSCLC患者高度的敏感性及特异性,具有筛选价值,节约社会资源,为广大肺癌患者服务.
Abstract
Objective To investigate the clinical value of antibody D5F3 and Survivin in patients with non small cell lung cancer.Methods 200 paraffin embedded specimens of patients with non small cell lung cancer tested by RT-PCR(including EML4-ALK mutant and wild type)from October 2012 to June 2014 were selected.The gene protein expression were tested by ALK new antibody D5F3 and the sensitivity and specificity were compared by negative and positive(+～3+).ResultsTest results show(+)the coincidence rate is 15.78％,(+ +)the coincidence rate is 27.27％and(+ + +)compliance rate was 87.5％,the difference was statistically significant(P<0.05).The expression of Survivin protein in NSCLC tissues was correlated with clinicopathological features.The positive rate of Survivin protein expression was correlated with the degree of differentiation(P<0.05),but not with other clinical and pathological features,with the decrease of differentiation,the positive rate of Survivin protein expression was significantly increased.Conclusion D5F3 and Survivin antibodies are highly sensitive and specific in patients with NSCLC,with the screening value,save social resources,for the majority of patients with lung cancer services.
关键词
D5F3/非小细胞肺癌/临床应用价值/EML4-ALK/SurvivinKey words
D5F3/non small cell lung cancer/clinical application value/EML4-ALK/Survivin引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据